New directions in natural killer cell-based immunotherapy of human cancer

Expert Opinion on Biological Therapy

Volumn 3, Issue 2, 2003, Pages 237-250

  Farag, Sherif S ^a,b   Fehniger, Todd A ^a   Becknell, Brian ^a   Blaser, Bradley W ^a   Caligiuri, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer; Immumotherapy; Interleukin 2; NK cells; Transplantation

Indexed keywords

ALPHA INTERFERON; CELL RECEPTOR; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2; LIGAND; MONOCLONAL ANTIBODY; RITUXIMAB; THALIDOMIDE; TRASTUZUMAB;

ALLOIMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL FUNCTION; CELL KILLING; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; NATURAL KILLER CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 0037391786     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.2.237     Document Type: Review

References (115)

1. ROSENBERG SA: Progress in human tumor immunology and immunotherapy. Nature (2001) 411:380-384.
2. HOROWITZ MM, GALE RP, SONDEL PM et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 75:555-562.
3. COLLINS RH JR, SHPILBERG O, DROBYSKI WR et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. (1997) 15:433-444.
4. KHOURI IF, SALIBA RM, GIRALT SA et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood (2001) 98:3595-3599.
5. CHILDS R, SRINIVASAN R: Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J. (2002) 8:2-11.
6. SLAVIN S, NAGLER A, SHAPIRA MY, AKER M, GABRIEL C, OR R: Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J. Clin. Immunol. (2002) 22:64-69.
7. YEE C, RIDDELL SR, GREENBERG PD: Prospects for adoptive T cell therapy. Curr. Opin. Immunol. (1997) 9:702-708.
8. ROBERTSON MJ, RITZ J: Biology and clinical relevance of human natural killer cells. Blood (1990) 76:2421-2438.
9. TRINCHIERI G: Biology of natural killer cells. Adv. Immunol. (1989) 47:187-376.
10. THOMPSON JA, SHULMAN KL, BENYUNES MC et al.: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J. Clin. Oncol. (1992) 10:960-968.
11. CALIGIURI MA, MURRAY C, ROBERTSON MJ et al.: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. (1993) 91:123-132.
12. SOIFFER RJ, MURRAY C, GONIN R, RITZ J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood (1994) 84:964-971.
13. COOPER MA, FEHNIGER TA, CALIGIURI MA: Biology of human natural killer cell subsets. Trends Immunol. (2001) 22:633-640. Detailed review of the biology of NK cell subsets.
14. dim NK cell subsets are functionally different rather than different stages in NK cell development.
15. CALIGIURI MA, ZMUIDZINAS A, MANLEY TJ, LEVINE H, SMITH KA, RITZ J: Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. (1990) 171:1509-1526.
16. BAUME DM, ROBERTSON MJ, LEVINE H, MANLEY TJ, SCHOW PW, RITZ J: Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur. J. Immunol. (1992) 22:1-6.
17. NAGLER A, LANIER LL, CWIRLA S, PHILLIPS JH: Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. (1989) 143:3183-3191.
18. ELLIS TM, FISHER RI: Functional heterogeneity of Leu 19'bright'+ and Leu 19'dim'+ lymphokine-activated killer cells. J. Immunol. (1989) 142:2949-2954.
19. ROBERTSON MJ, SOIFFER RJ, WOLF SF et al.: Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. (1992) 175:779-788.
20. VOSS SD, DALEY J, RITZ J, ROBERTSON MJ: Participation of the CD94 receptor complex in costimulation of human natural killer cells. J. Immunol. (1998) 160:1618-1626.
21. ANDRE P. SPERTINI O, GUIA S et al.: Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. Proc. Natl. Acad. Sci. USA (2000) 97:3400-3405.
22. LJUNGGREN HG, KARRE K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today (1990) 11:237-244.
23. ZIJLSTRA M, AUCHINCLOSS H JR, LORING JM, CHASE CM, RUSSELL PS, JAENISCH R: Skin graft rejection by beta 2-microglobulin-deficient mice. J. Exp. Med. (1992) 175:885-893.
24. ROUTES JM: IFN increases class I MHC antigen expression on adenovirus-infected human cells without inducing resistance to natural killer cell killing. J. Immunol. (1992) 149:2372-2377.
25. MALNATI MS, LUSSO P, CICCONE E, MORETTA A, MORETTA L, LONG EO: Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements. J. Exp. Med. (1993) 178:961-969.
26. LANIER LL: Activating and inhibitory NK cell receptors. Adv. Exp. Med. Biol. (1998) 452:13-18. Detailed review of NK cell receptor biology.
27. LOPEZ-BOTET M, BELLON T: Natural killer cell activation and inhibition by receptors for MHC class I. Curr. Opin. Immunol. (1999) 11:301-307. Review of KIRs.
28. MORETTA A, BOTTINO C, VITALE M et al.: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann. Rev. Immunol. (2001) 19:197-223. Review of activating NK cell receptor biology.
29. FARAG SS, FEHNIGER TA, RUGGERI L, VELARDI A, CALIGIURI MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood (2002) 100:1935-1947.
30. BAKKER AB, WU J, PHILLIPS JH, LANIER LL: NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum. Immunol. (2000) 61:18-27. Review of intracellular pathways of signal transduction by of NK cell receptors.
31. LANIER LL: Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell (1998) 92:705-707.
32. LOPEZ-BOTET M, BELLON T, LLANO M, NAVARRO F, GARCIA P, DE MIGUEL M: Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum. Immunol. (2000) 61:7-17.
33. VALES-GOMEZ M, REYBURN HT, MANDELBOIM M, STROMINGER JL: Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity (1998) 9:337-344.
34. MORETTA A, BOTTINO C, VITALE M et al.: Receptors for HLA class-I molecules in human natural killer cells. Ann. Rev. Immunol. (1996) 14:619-648.
35. WAGTMANN N, RAJAGOPALAN S, WINTER CC, PERUZZI M, LONG EO: Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and functional transfer. Immunity (1995) 3:801-809.
36. LANIER LL: NK cell receptors. Ann. Rev. Immunol. (1998) 16:359-393.
37. RAJAGOPALAN S, LONG EO: A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. (1999) 189:1093-1100.
38. IBRAHIM EC, GUERRA N, LACOMBE MJ et al.: Tumor-specific upregulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. (2001) 61:6838-6845.
39. WIENDL H, MITSDOERFFER M, HOFMEISTER V et al.: A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. (2002) 168:4772-4780.
40. UGUREL S, REINHOLD U, TILGEN W: HLA-G in melanoma: a new strategy to escape from immunosurveillance? Onkologie (2002) 25:129-134.
41. UROSEVIC M, WILLERS J, MUELLER B, KEMPF W, BURG G, DUMMER R: HLA-G protein upregulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood (2002) 99:609-617.
42. BAUER S, GROH V, WU J et al.: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285:727-729. Discusses the biology of MICA/B as ligands for NKG2D.
43. SIVORI S, PAROLINI S, MARCENARO E et al.: Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J. Neuroimmunol. (2000) 107:220-225.
44. PENDE D, CANTONI C, RIVERA P et al.: Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur. J. Immunol. (2001) 31:1076-1086. Relative roles of NKG2D and NCR in the recognition and killing of tumour cells by NK cells.
45. COSTELLO RT, SIVORI S, MARCENARO E et al.: Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 99:3661-3667. Presents evidence for a reduction in expression and function of activating NK cell receptors in patients with advanced leukaemia.
46. BAHRAM S: MIC genes: from genetics to biology. Adv. Immunol. (2000) 76:1-60.
47. WU J, SONG Y, BAKKERAB et al.: An activating immunoreceptor complex formed by NKG2D and DAP10. Science (1999) 285:730-732.
48. SUTHERLAND CL, CHALUPNY NJ, COSMAN D: The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol. Rev. (2001) 181:185-192. A significant paper characterising the ULBPs as important ligands for NKG2D.
49. COSMAN D, MULLBERG J, SUTHERLAND CL et al.: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 14:123-133.
50. GROH V, RHINEHART R, SECRIST H, BAUER S, GRABSTEIN KH, SPIES T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad Sci. USA (1999) 96:6879-6884.
51. GROH V, BAHRAM S, BAUER S, HERMAN A, BEAUCHAMP M, SPIES T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad Sci. USA (1996) 93:12445-12450.
52. GROH V, RHINEHART R, RANDOLPH-HABECKER J, TOPP MS, RIDDELL SR, SPIES T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. (2001) 2:255-260.
53. CERWENKA A, BARON JL, LANIER LL: Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA (2001) 98:11521-11526.
54. PESSINO A, SIVORI S, BOTTINO C et al.: Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. (1998) 188:953-960.
55. SUTHERLAND CL, CHALUPNY NJ, SCHOOLEY K, VANDENBOS T, KUBIN M, COSMAN D: UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. (2002) 168:671-679.
56. SILICIANO RF, PRATT JC, SCHMIDT RE, RITZ J, REINHERZ EL: Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 317:428-430.
57. LANIER LI, RUITENBERG JJ, PHILLIPS JH: Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J. Immunol. (1988) 141:3478-3485.
58. TIMONEN T, PATARROYO M, GAHMBERG CG: CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J. Immunol. (1988) 141:1041-1046.
59. CARBONE E, RUGGIERO G, TERRAZZANO G et al.: A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. Journal of Experimental Medicine (1997) 185:2053-2060.
60. BORREGO F, ROBERTSON MJ, RITZ J, PENA J, SOLANA R: CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology (1999) 97:159-165.
61. TANGYE SG, CHERWINSKI H, LANIER LL, PHILLIPS JH: 2B4-mediated activation ofhuman natural killer cells. Mol. Immunol. (2000) 37:493-501.
62. SIVORI S, PAROLINI S, FALCO M et al.: 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. (2000) 30:787-793.
63. BOTTINO C, FALCO M, PAROLINI S, et al.: NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J. Exp. Med. (2001) 194:235-246.
64. VITALE M, FALCO M, CASTRICONI R et al.: Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur. J. Immunol. (2001) 31:233-242.
65. ROSENBERG SA, LOTZE MT, MUUL LM et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. (1985) 313:1485-1492.
66. KIMURA H, YAMAGUCHI Y: A Phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer (1997) 80:42-49.
67. LAW TM, MOTZER RJ, MAZUMDAR M et al.: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 76:824-832.
68. CALIGIURI MA, MURRAY C, SOIFFER RJ et al.: Extended continuous infiasion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J. Clin. Oncol. (1991) 9:2110-2119.
69. MEROPOL NJ, BARRESI GM, FEHNIGER TA, HITT J, FRANKLIN M, CALIGIURI MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. (1998) 46:318-326. Describes the in vivo effects on NK cell expansion and activation of the low-dose IL-2 with intermediate-dose pulse IL-2 regimen.
70. FARAG SS, GEORGE SL, LEE EJ et al.: Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin. Cancer Res. (2002) 8:2812-2819.
71. ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. (1999) 17:2105-2116. Therapeutic benefit of high-dose IL-2 in metastatic melanoma.
72. PARKINSON DR, SZNOL M: High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Semin. Oncol. (1995) 22:61-66.
73. BENYUNES MC HIGUCHI C, YORK A et al.: Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant. (1995) 16:283-288.
74. BAUER M, REAMAN GH, HANK JA et al.: A Phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer (1995) 75:2959-2965.
75. SHIBAGAKI R, ISHIMOTO S, TAKENAKA H, YASUNO H: Recombinant interleukin 2 monotherapy for classic Kaposi sarcoma. Arch. Dermatol. (1998) 134:1193-1196.
76. FISHER RI, ROSENBERG SA, FYFE G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. (2000) 6:S55-S57. Updated results of the beneficial effect of high-dose IL-2 in metastatic renal cell carcinoma.
77. MELONI G, VIGNETTI M, POGLIANI E et al.: Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer. Sci. Am. (1997) 3:S43-S47.
78. ROSENBERG SA YANG JC, SCHWARTZENTRUBER DJ et al.: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination, vith interleukin-2 and interferon alfa-2b. J. Clin. Oncol. (1999) 17:968-975.
79. BAXEVANIS CN, DEDOUSSIS GV, PAPADOPOULOS NG et al.: Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Cancer (1995) 76:1253-1260.
80. DAVIES FE, RAJE N, HIDESHIMA T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98:210-216.
81. GOLAB J, ZAGOZDZON R: Antitumor effects of interleukin-12 in pre-dinical and early clinical studies (Review). Int. J. Mol. Med. (1999) 3:537-544. Review of clinical trials of IL-12 in cancer.
82. LIM SH, NEWLAND AC, KELSEY S et al.: Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia-a Phase II study. Cancer Immunol. Immunother. (1992) 34:337-342.
83. CORTES JE, KANTARJIAN HM, O'BRIEN S et al.: A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer (1999) 85:1506-1513.
84. ITESCU S, ARTRIP JH, KWIATKOWSKI PA et al.: Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products. Ann. Transplant. (1997) 2:14-20.
85. WETZLER M, BAER MR, STEWART SJ et al.: HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia (2001) 15:128-133.
86. IGARASHI T, SRINIVASAN R, WYNBERG J et al.: Generation of alloreactive NK cells with selective cytotoxicity to melanoma and renal cell carcinoma based on KIR-ligand incompatibility. Blood (2002) 100:73a. An abstract presenting for the first time evidence for the effect of KIR epitope mismatching on alloreactivity of NK cells against solid tumour cell.
87. FROHN C, HOPPNER M, SCHLENKE P, KIRCHNER H, KORITKE P, LUHM J: Anti-myeloma activity of natural killer lymphocytes. Br. Haematol. (2002) 119:660-664.
88. WEINER M: Monoclonal antibody therapy in cancer. Semin. Oncol. (1999) 26:43-51.
89. GOLAY J, ZAFFARONI L, VACCARI T et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95:3900-3908.
90. HARJUNPAA A, JUNNIKKALA S, MERI S: Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. (2000) 51:634-641.
91. HOFMEISTER JK, COONEYD D, COGGESHALL KM: Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. (2000) 26:133-143.
92. REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435-445.
93. CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6:443-446. Presents evidence for the importance of ADCC as a mechanism for the in vivo activity of rituximab.
94. KONO K, TAKAHASHI A, ICHIHARA F, SUGAI H, FUJII H, MATSUMOTO Y: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. (2002) 62:5813-5817.
95. MASUCCI G, RAGNHAMMAR P, WERSALL P, MELLSTEDT H: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol. Immunother. (1990) 31:231-235.
96. CARSON WE, PARIHAR R, LINDEMANN MJ et al.: Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. (2001) 31:3016-3025.
97. PARIHAR R, DIERKSHEIDE J, HU Y, CARSON WE: IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J. Clin. Invest. (2002) 110:983-992.
98. NGUYEN QH, ROBERTS RL, ANK BJ, LIN SJ, THOMAS EK, STIEHM ER: Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells. Cell Immunol. (1998) 185:83-92.
99. DABHOLKAR M, TATAKE R, AMIN K, ADVANI S, GANGAL S: Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission. Oncology (1989) 46:123-127.
100. HANK JA, ROBINSON RR, SURFUS J et al.: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. (1990) 50:5234-5239.
101. FRIEDBERG JW, NEUBERG D, GRIBBEN JG et al.: Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol. (2002) 117:828-834.
102. ANSELL SM, WITZIG TE, KURTIN PJ et al.: Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 99:67-74.
103. WENG W, LEVY R: Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma. Blood (2002) 100:157a.
104. KOH CY, BLAZAR BR, GEORGE T et al.: Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood (2001) 97:3132-3137. In vivo use of antibody to block KIR-MHC class I interaction as a means to augment NK cell-mediated killing of neoplastic cells.
105. VITALE M, BOTTINO C, SIVORI S et al.: NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major hisrocompatibility complex-restricted tumor cell lysis. J. Exp. Med. (1998) 187:2065-2072.
106. SANTOURLIDIS S, TROMPETER HI, WEINHOLD S et al.: Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. Immunol. (2002) 169:4253-4261.
107. GUR H, KRAUTHGAMER R, BERREBI A et al.: Tolerance induction by megadose hematopoeitic progenitor cells: expansion of veto cells by short term culture of purified human CD 34(+) cells. Blood (2002) 99:4174-4181.
108. MARTELLI MF, AVERSA F, BACHAR-LUSTIG E et al.: Transplants across human leukocyte antigen barriers. Semin. Hematol. (2002) 39:48-56.
109. RUGGERI L, CAPANNI M, CASUCCI M et al.: Role of natural killer cell alloreactivity in HLA-mismatched hemaropoietic stem cell transplantation. Blood (1999) 94:333-339.
110. COLONNA M, BORSELLINO G, FALCO M, FERRARA GB, STROMINGER JL: HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. USA (1993) 90:12000-12004.
111. MANDELBOIM O, REYBURN HT, VALES-GOMEZ M et al.: Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J. Exp. Med. (1996) 184:913-922.
112. RUGGERI L, CAPANNI M, URBANI E et al: Effectiveness of donor natural killer call alloreactivity in mismatched hematopoietic transplants. Science (2002) 295:2097-3100. Excellent review by the Perugia group of the biology and clinical efficacy of alloreactive NK cells in the setting of haplotype-mismatched stem cell transplants.
113. DAVIES SM, RUGGERI L, DEFOR T et al.: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 100:3825-3827.
114. GEIBELS, LOCATELLI F, MACCARIO R et al.: KIR ligand incompatibility is associated with prolonged survival and lower transplant-related mortality in URD-HSCT recipients. Blood (2002) 100:640a.
115. KEEVER CA, SMALL TN, FLOMENBERG N et al.: Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood (1989) 73:1340-1350.